Check six MEDDICC figures before a forecast call: cycle length, buyer coverage, quantified outcomes, dated steps, champion evidence, and vendor adoption and pricing claims.
Key takeaways
- Compare planned close dates with your own closed-deal cycle lengths.
- Confirm budget authority and record buyer-backed metrics.
- Tie decision and paper steps to dated buyer events.
- Keep training counts and prices separate from evidence of forecast performance.
Where the method and its numbers come from
If you sit in deal reviews long enough, you will hear the same letters again and again. MEDDICC is a sales qualification framework. Each letter stands for a question a seller should be able to answer about a deal, such as what the business outcome is worth, who has the budget, and what the buying steps look like. The idea is simple. A deal with clear answers is more likely to close, so a forecast built on those answers should be more trustworthy than one built on a rep's gut feeling.
Revenue leaders often inherit a framework partway through its life. The question is rarely whether the vocabulary is useful. It is whether the numbers that come with it can survive a skeptical look from the person who signs off on the forecast.
The framework has a history you can check. The vendor's own MEDDICC methodology page says that MEDDIC was originally created inside PTC in 1996 by Dick Dunkel. It also says the framework became the foundation for how enterprise B2B sales teams qualify, forecast and close complex deals worldwide. That last line is a claim by the vendor, not an independent measurement. It tells you where the method came from. It does not tell you how well the method works for your team.
That distinction matters for everything else in this post. MEDDICC is sold as a methodology, and the company that teaches it publishes figures about it. Some of those figures are useful prompts for a review. Others are marketing. The goal is to know which is which before you let a number shape a forecast call.
Read each figure below with three questions in mind. What exactly does it measure? Who collected it, and how? And what would you need to see in your own pipeline to believe it applies to you?
1. Time to attainment
The MEDDICC page says: "Time to attainment is too long, in some cases over 12 months."
The quoted line does not define "time to attainment" in the sentence itself. Before you use the figure, find out what the clock starts and stops on. Is it the first call, the first qualified opportunity, or the signed contract? Does it include the time a deal sits idle waiting for a buyer? If the definition is unclear, the number tells you almost nothing about your own cycle length.
That duration is not an average for your industry, your deal size, or your product. In a forecast review, the useful move is to pull your own closed deals, measure their cycle length with the same start and stop points, and compare that to your planned close dates. If your open deals are dated for close inside a window that your own history rarely supports, the forecast is at risk, whatever any vendor says about typical timelines.
Ask one question in the review. "What is our actual time from qualified opportunity to closed deal, using the same definition we use for the forecast?" If nobody can answer it quickly, the forecast is resting on a figure nobody has checked.
A practical way to test the cycle is to split it into the stages your CRM already tracks. If most of the elapsed time sits in one stage, such as the wait for a procurement response, that stage is where the close date is most likely to slip. Ask about it first.
2. Economic buyer coverage
The idea is that a deal should have a named person who controls the budget and can approve the purchase. A forecast built on deals without that name is built on hope.
The figure to read here is not a percentage from the vendor. It is a count you can make yourself. Go through every deal in the commit and best-case categories and ask a plain question: is the economic buyer named in our notes, and has that person been in a conversation with us? Write down how many deals pass. Then look at the dollar value of the ones that fail.
Two checks make this figure more honest. First, watch for deals where the rep has named someone who sounds senior but has no budget authority. A title is not the same as control over money. Second, watch for deals where the economic buyer has been named but never met. A name in a field is not coverage.
When you review this field, also check whether the same name appears across several deals in one account. If a single contact carries every deal in an account, that account has coverage, but it also has a single point of failure. A change in that person's role can move several forecast lines at once. Note those accounts in the review.
In the review, treat a deal without a confirmed economic buyer as a risk line, not a closed question. You do not need to remove it from the forecast automatically. You do need to say what it would take to confirm the person and when that will happen.
3. Metrics tied to a dollar value
The metrics letter asks the seller to quantify the business case. The buyer should be able to say what the problem costs, what the improvement is worth, and how that compares with the price. In a forecast call, a deal with a clear metric is easier to defend because the buyer has already done some of the justification work.
The figure to read here is the share of your open pipeline that has a written, quantified outcome. Again, you can measure it yourself. Pull the list of open opportunities and check whether each has a number in the metrics field, and whether that number came from the buyer or from the seller. A number the seller invented to fill a box is weaker than one the buyer confirmed in a meeting.
Metrics also need a time frame. A benefit stated without a period, such as a saving with no year attached, is hard to compare with the price or with the buyer's budget cycle. In the review, ask the rep to restate each metric with its period, its unit, and the person on the buyer's side who agreed to it. Restated this way, a metric becomes a claim you can check rather than an impression.
Be wary of precision that looks better than it is. A single exact-looking savings total may sound rigorous, but if no one can say where it came from, it is a guess dressed up as analysis. Ask the rep to show the source, such as a finance assumption, a budget line, or a statement from the buyer. If the source is a feeling, label the deal as unquantified in the forecast notes.
This figure also tells you something about deal size. If your small deals never show a quantified outcome, that is a process signal worth raising, even if those deals close anyway.
4. Dated decision and paper steps
MEDDICC includes questions about the decision process and, in the MEDDPICC variant, the paper process. Put simply, these ask how the buyer will decide, what steps come next, and what legal, procurement, and approval work sits between a verbal yes and a signed contract.
The figure to read here is the number of open deals with a dated next step for each stage that the buyer has described. A deal that says "decision in Q4" with no approval meeting, no procurement contact, and no legal review on the calendar has a date that no one has tested. The date is a hope written in the CRM.
When you look at these fields, check three things. Is each date tied to a real event on the buyer's side, such as a budget cycle, a board meeting, or a signature deadline the buyer named? Has the date moved since the last review, and if so, why? And does the paper process list the actual people who must sign off, rather than a general phrase such as "legal will review"?
Watch for the difference between a date the buyer named and a date the seller chose. A signature date that comes from the buyer's own process is far stronger than a close date the rep set to match the end of the quarter. If the two differ, the review should record which is which, because the forecast is only as firm as the weaker of the two. Use a close date change log to record why a date moved.
A forecast call is a good place to ask for the paper process in plain terms. "What happens between now and signature, who owns each step, and what is the earliest that step can finish?" If the answer is vague, the deal's close date should be treated with suspicion, however confident the rep sounds.
5. Champion strength and competition
Two more letters deserve a place in your review: the champion and competition. A champion is an internal person who wants the deal to happen and is willing to help you win it. Competition is the set of alternatives the buyer is considering, including doing nothing.
The figure to read here is a qualitative judgment that you can make consistent. For each large deal, ask whether the champion has shown real influence, such as sharing internal information, introducing you to the economic buyer, or pushing a decision forward when the calendar slips. A friendly contact who answers emails is not the same thing. Note the evidence in the deal record. A champion who has no evidence of influence should lower your confidence in the close date.
It also helps to ask what the champion would lose if the deal failed. A champion with a personal stake, such as owning the project or being measured on its result, is more likely to act when the timeline slips. A champion who will not be affected either way may be friendly without being useful. This is a judgment call, so write down the reasoning, not just the label.
On competition, the question is whether the rep knows who else is in the running and why the buyer might choose them. If a deal lists no competitor at all, that is not proof the deal is safe. It may mean the rep has not asked. Ask the rep to name the most likely alternative, including "no decision" or a delay, and to say what would make the buyer pick it.
These two letters are harder to measure than the others. That is a reason to be more explicit in the review, not less. Write down the evidence, and make sure two people can read the same notes and reach the same view.
6. The vendor's own adoption and pricing figures
The last set of figures is the one most likely to shape a buying decision for your team, and it is the one least related to forecast accuracy. The MEDDICC page says that "MEDDICC plans start at $499 per year for the MEDDPICC Masterclass, with Individual and Small Team (2-10) Membership at $899 per year." It also says the training has been "taken by 25,000+ students," and describes membership as a way to "embed MEDDPICC into your day-to-day operations."
Read these as vendor-reported figures about the vendor's business, not about your results. The price tells you what a team might spend to learn the framework and the vocabulary. The student count tells you how many people have taken the training. Neither figure says whether deals trained on MEDDICC close at a higher rate, whether forecasts become more accurate, or whether sales cycles get shorter.
This is not a reason to dismiss the framework. But if someone in your organization argues that a published number proves MEDDICC works, ask what the number measures and whether the comparison group is clear.
If your team does decide to adopt the framework, use the same discipline you would apply to any tool. Set a baseline before training. Measure the same figures afterward. Compare forecast accuracy and cycle length over several quarters, not a single call. That gives you your own figures to read, which will be more useful than anything published about the method.
How to use these figures in the review
You do not need a dashboard to start. Before your next forecast call, pick three of the six figures above and measure them for your top twenty open deals. Write the results in a single table: deal name, amount, whether the economic buyer is confirmed, whether the metric is quantified and sourced, and whether the next dated step is tied to a real buyer event. Use "unconfirmed" or "unquantified" where evidence is missing, rather than leaving cells empty.
Then run the review around that table. Spend the most time on deals where the numbers disagree with the rep's confidence. A large deal with a strong champion but no confirmed economic buyer is a different conversation from a small deal with everything in place. The table helps you ask the right question for each one.
Share the table with the rep before the call, not during it. Reps who see the same columns can prepare, and the conversation shifts from defending a number to closing the gaps in it. Over a few quarters, track which unconfirmed entries gain supporting evidence.
Illustrative example: test a planned close date
Ask which buyer-confirmed steps support the shorter timeline. Record the explanation and any missing approval dates before reviewing the close date. The difference prompts a question; it does not prove the deal will slip.
Take the next step today
Pick an open deal and check its buyer, quantified outcome and next dated step. Record the missing evidence and agree with the rep who will confirm it before the next forecast call.
Questions before the forecast call
Should a deal without a confirmed economic buyer leave the forecast?
You do not need to remove it automatically; record the risk and what would confirm budget authority. Give the confirmation work an owner and a date.
Is champion strength a numerical figure?
Champion strength is a qualitative judgment based on evidence of influence. Keep the reasoning beside the label so another reviewer can assess it.